Ayvakit
| Chemical Name | avapritinib |
| Dosage Form | Tablet (oral; 100 mg, 200 mg, 300 mg) |
| Drug Class | Kinase inhibitors |
| System | Digestive |
| Company | Blueprint Medicines |
| Approval Year | 2020 |
Indication
- Ayvakit is indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.